Navigation Links
Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
Date:9/4/2009

STOCKHOLM, September 4 /PRNewswire/ -- Karolinska Development (publ) today announced that one of its portfolio companies, Dilafor AB, has concluded an extensive clinical study of its candidate drug, tafoxiparin, a new drug substance for the prevention of protracted labor during childbirth. The promising results of the Phase II trial bring the project closer to exit in line with Karolinska Development's business strategy.

Dilafor's candidate drug, tafoxiparin DF01 is one of 11 compounds within the Karolinska Development portfolio that are currently conducting clinical trials. The completion of the Dilafor study is an important milestone for Karolinska Development and exemplifies the company's ability to develop innovative ideas through to clinical proof of concept quickly and efficiently. In the case of Dilafor, tafoxiparin has taken just six years to go from research concept to its current stage.

Karolinska Development's portfolio consists of more than 40 life science companies. A unique business model, which gives portfolio companies access to a broad network of business, legal, regulatory and scientific expertise, means that development times and costs are reduced compared to traditional drug development programs. With seven compounds currently undergoing Phase II clinical trials and five in Phase I the portfolio has matured to the point that Karolinska Development is now actively seeking commercial partners for its most advanced projects.

Conny Bogentoft, CEO of Karolinska Development, said, "The completion of the Dilafor Phase II trial is an important step for Karolinska Development and we are extremely pleased that Dilafor has achieved some very positive results. At the same time, it also goes a long way towards validating our business model. We are now very much focused on finding commercial opportunities for Dilafor's tafoxiparin and for several of our other projects that are reachin
'/>"/>

SOURCE Karolinska Development AB PUBL
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
2. Karolinska Development Closes Fully Subscribed New Share Issue
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
5. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
6. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
7. Global Experts Explore Entire Spectrum of Aids Vaccine Development
8. Vical Names Andrew de Guttadauro Vice President, Corporate Development
9. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
10. SemBioSys updates Apo AI development program
11. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
(Date:1/15/2014)... 15, 2014 Two champions of science, ... sponsorship of an annual competition for middle and high ... to, innovative STEM study. The competition presents students with ... of Engineering Aptitude, Mathematics, and Sciences is a ...
(Date:1/15/2014)... January 15, 2014 AudioNotch is the ... therapy for the treatment of tinnitus. Patients listen to ... and over a period of weeks to months, their tinnitus ... in two forms: Notched Music and Notched White Noise. Now, ...
(Date:1/14/2014)...  3D Communications, a leading provider of strategic communications services to corporations ... in the United States and ... , JD, is returning to the firm,s Washington, D.C. ... after more than two years of service as Associate Commissioner for ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Former FDA Associate Commissioner Returns To 3D Communications 2
... NEW YORK, May 5, 2011 Reportlinker.com announces ... in its catalogue: Tumor Markers ... Forecasts to 2017 http://www.reportlinker.com/p0490349/Tumor-Markers---Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2017.html ... Analysis, Competitive Landscape and Market Forecasts to 2017 ...
... May 4, 2011 Highlights First Quarter ... ("FFO") Per Share (Diluted) Attributable to Alexandria Real Estate Equities, ... on Early Extinguishment of Debt, Up 6% Compared to First ... Quarter 2011 Earnings Per Share (Diluted) Attributable to Alexandria Real ...
... May 4, 2011 Beardsworth announces the promotion of ... Operations and Project Management and the addition of ...   (Photo:   http://photos.prnewswire.com/prnh/20110504/NY95605 ) ... Beardsworth,s expanded focus in oncology clinical operations and execution ...
Cached Biology Technology:Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 2Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 3Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 4Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 5Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 6Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 7Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 8Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 9Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 10Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 11Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 12Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 13Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 14Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 2Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 3Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 4Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 5Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 6Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 7Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 8Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 9Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 10Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 11Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 12Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 13Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 14Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 15Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 16Beardsworth Continues to Strengthen Oncology Operations 2
(Date:4/18/2014)... researchers led by a University of California, Riverside professor ... million Department of Defense grant to uncover fundamental design ... the predictable design of light-weight, tough and strong advanced ... plants and animals, including the mantis shrimp, toucan and ... constructed over millions of years and coming up with ...
(Date:4/17/2014)... for chili peppers. Information about archaeological remains of ancient ... the appearance of words for chili peppers in ancient ... and highlight the value of multi-proxy data analysis. Their ... nine papers presented in a special feature issue of ... on plant and animal domestication edited by Dolores ...
(Date:4/17/2014)... Professor Luca Razzari of the nergie Matriaux Tlcommunications ... from the John R. Evans Leaders Fund of ... acquisition of state-of-the-art biotech and nanophotonics equipment. To ... the Ministre de l,Enseignement suprieur, de la Recherche, ... These new laboratories will help us develop new ...
Breaking Biology News(10 mins):Mantis shrimp, toucan and trilobite, oh my 2Mantis shrimp, toucan and trilobite, oh my 3Chickens to chili peppers 2Chickens to chili peppers 3New state-of-the-art biotech and nanotech equipment for INRS 2
... before and after a rather decadent meal. But it ... a virus, before and after cramming itself full of its ... that pumps its DNA into the capsid—outer shell—during the assembly ... may help phi29 inject its genetic material into the bacterial ...
... A key hormone enables starving mice to alter their ... molecular target for drugs to treat human obesity and ... , The starvation-fighting effects of the hormone, called ... first time in a study appearing online today in ...
... global warming debate has focused on carbon dioxide emissions, ... lesser-known mechanism -- dirty snow -- can explain one-third ... greenhouse gases. , Snow becomes dirty when soot from ... and falls to the ground. Soot-infused snow is darker ...
Cached Biology News:Hormone helps mice 'hibernate,' survive starvation 2Dirty snow may warm Arctic as much as greenhouse gases 2
X-Gal (5-Bromo-4-Chloro-3-Indoyl-beta -D-Galactopyranoside)...
Oligodendrocyte Marker O1 MAb (Clone O1)...
Mouse/Rat WNK1 Affinity Purified Polyclonal Ab...
RayBio L Series 507: RayBio Label-based Antibody Array I (2 membranes) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: